Non-small-cell lung cancer (NSCLC) accounts for approximately 70-80% of all lung cancers 2 and oncogenic activation of receptor tyrosine kinases (RTKs), such as epidermal growth factor receptor (EGFR), is especially relevant for this disease 3. This evidence concerns the gene EGFR and lung cancer.